BioSpace News Archive

AUSTEDO® was approved by the U.S. FDA for the treatment of chorea associated with Huntington’s disease in April 2017 and for tardive dyskinesia in adults in August 2017.

Company marks Rare Disease Day 2018 with continued commitment to reduce time to diagnosis of rare diseases.

Held at Elevate by Psych Congress, a gathering of up-and-coming leaders in mental health care, the event featured some of the most groundbreaking technologies in the mental health marketplace.

Partnership to improve awareness of, access to, and participation in clinical trials for U.S. physicians and patients.

America’s Eco-CEO, Kelly Vlahakis-Hanks, Reminds Shoppers That Safer Alternatives Exist - Look For EPA’s ‘Safer Choice’ Label

Positive clinical data demonstrated the ability of the ISCDxtm Test to identify cause of ischemic stroke.

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced its entry into a definitive agreement with Destum Partners, Inc., a leading strategic advisory firm serving companies in the life sciences industry, to assist in its pharma partnering activities.

As National Presenting Sponsor of the 2018 Kidney Walks, FMCNA Pledges $750,000 toward Kidney Disease Research and Support

- Fourth Quarter 2017 GAAP Revenue of $146.9 million, up 49% year over year - Full Year 2017 GAAP Revenue of $521 million - Full Year 2017 GAAP Net Income of $60 million - Full Year 2017 GAAP Diluted Earnings Per Share of $1.13 - Full Year 2017 Adjusted Earnings Per Share of $1.60 - Full Year 2017 Adjusted EBITDA of $106 million

Podcast continues legacy of the ‘Rare in Common’ film by bringing awareness to the experiences of patients with rare diseases and their advocate communities